

Eosinophilic oesophagitis (EoE) causing food bolus obstruction in adults: an integrated pathway

For patients aged 18+ years

Development of this optimal pathway was supported by Wilmington Healthcare, funded by an educational grant from Dr Falk.



Wilmington
Healthcare

Foreword

Failure to diagnose eosinophilic oesophagitis (EoE) is a serious barrier to optimal patient care, resulting in a cycle of persistent episodes of food bolus obstruction (FBO), sometimes leading to repeat attendances at accident and emergency (A&E) departments and delays before appropriate treatment. Even once the condition is diagnosed, delays in starting licensed treatment and logistical issues with repeat prescribing can impact on the patient's management. A clear integrated pathway is needed to optimise the management of the increasing number of patients with this chronic condition.


EoE is a chronic condition in which eosinophils infiltrate the oesophageal epithelium and fibrosis develops in the submucosa.¹⁻⁷ It is characterised clinically by symptoms related to oesophageal dysfunction, such as solid-food dysphagia, food impaction, and non-swallowing-/swallowing-related chest pain and histologically by eosinophil-predominant inflammation.^{1,2,8-10}

Patients with EoE typically have the condition for many years and become used to being aware of food travelling down their oesophagus.^{8,10} They may adapt their eating in order to avoid these sensations – for example, drinking large amounts of water or only eating foods that are known to travel smoothly down the oesophagus.¹⁰ They are prolonged chewers, slow to eat and the last to finish a meal,⁸ so they often avoid eating out and become socially isolated.

Rarely detected 30 years ago, EoE is becoming common. Pooled estimates of global annual incidence and prevalence are 5.3 and 40/100,000 population, respectively,⁷ but US and European prevalence rates are much higher at 79-118/100,000.^{4,6}

The observed increase is a real increase in disease frequency, as it is mirrored by an increase in the frequency of FBO presenting to A&E departments. Indeed, FBO is now one of the most common gastrointestinal emergency admissions.

Guidelines developed by the British Society of Gastroenterology (BSG) and British Society of Paediatric Gastroenterology and Nutrition (BSPGHAN)¹¹ give clear guidance on what should be done for these patients. If these guidelines could be followed, the quality of patient care would be dramatically improved, providing clear diagnosis, effective treatment, and cost efficiency for both the health service and the patient.



Professor Stephen E Attwood
Honorary Professor, Health Services Research,
Durham University, UK

This document sets out an optimal pathway based on recommended best practice for the management of EoE. It has been developed based on consensus of expert groups combined with insights from interviews with stakeholders involved at all stages of the pathway. It behoves clinicians in primary care and each hospital trust to put this into practice – the sooner the better, given how quickly the incidence of EoE is rising.²






How to use this document

The integrated care pathway is used as a menu system for this interactive document.

The pathway is divided into three sections, with an algorithm and bulleted list of actions for each stage of the pathway. The sections are colour coded throughout the document:




CLICK ON THE ICONS

-  Information button for more detail
-  Forward button to move to the next page
-  Back button to move to the previous page
-  Close button to return to the pathway
-  Home button to return to the full pathway

[Appendix 1](#) contains a list of references used in this document, which can be accessed through the button on each page.

Overview of the pathway



*Formerly per high-power field. ** Ensure appropriate maintenance shared care treatment plan is in place.
 A&E, accident and emergency; EoE, eosinophilic oesophagitis; GP, general practitioner; ODT, oral dispersible tablet; OGD, oesophago-gastro-duodenoscopy; PCN, primary care network; PIFU, patient-initiated follow-up; PPI, proton pump inhibitor.

Initial management

Long-term management

References (1)

1. Attwood SEA, Smyrk TC, Demeester TR. Esophageal asthma – an episodic dysphagia with eosinophilic infiltrates. *Gut* 1989;30:A1493
2. Attwood SE, Smyrk TC, Demeester TR, Jones JB. Esophageal eosinophilia with dysphagia. A distinct clinicopathologic syndrome. *Dig Dis Sci* 1993;38:109–116.
3. Navarro P, Arias A, Arias-González L, et al. Systematic review with meta-analysis: the growing incidence and prevalence of eosinophilic oesophagitis in children and adults in population-based studies *Aliment Pharmacol Ther* 2019;49:1116–25.
4. Limketkai BN, Shah SC, Hirano I, et al. Epidemiology and implications of concurrent diagnosis of eosinophilic oesophagitis and IBD based on a prospective population-based analysis. *Gut* 2019;68:2152–60.
5. Allin KG, et al. Eosinophilic oesophagitis in Denmark: population-based incidence and prevalence in a nationwide study from 2008 to 2018. *United European Gastroenterol J* 2022;10:640–50.
6. Plate J, Söderbergh S, Larsson H. Eosinophilic esophagitis, prevalence, incidence and presenting features in Southwest Sweden: a 20-year population-based study. *United European Gastroenterol J* 2022;10(Suppl 8):507 (P0060).
7. Hahn JW, Lee K, Shin Jae I, et al. Global incidence and prevalence of eosinophilic esophagitis 1976–2022: a systematic review and meta-analysis. *Clin Gastro Hepatol* 2023;16:doi:10.1016/j.cgh.2023.06.005.
8. Attwood S. Eosinophilic oesophagitis – a common disease, newly recognised. *Clin Med* 2013;13:s32–5.
9. Lucendo AJ, Molina-Infante J, Arias A, et al. Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. *United European Gastroenterol J* 2017;5:335–58.
10. Dellon ES. *Eosinophilic esophagitis (EoE)*. Available at: www.med.unc.edu/medicine/news/chairs-corner/podcast/eoe-dellon (accessed 1 February 2024).
11. Dhar A, Haboubi HN, Attwood SE, et al. British Society of Gastroenterology (BSG) and British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) joint consensus guidelines on the diagnosis and management of eosinophilic oesophagitis in children and adults. *Gut* 2022;71:1459–87.
12. Biederman L, Straumann A. Mechanisms and management of eosinophilic oesophagitis: an overview. *Nature Rev Gastroenterol Hepatol* 2023;20:101–19.
13. Hirano I, Dellon ES, Hamilton JD, et al. Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic oesophagitis. *Gastroenterology* 2020;158:111–22
14. Yantiss RK, Odze RD. Optimal approach to obtaining mucosal biopsies for assessment of inflammatory disorders of the gastrointestinal tract. *Am J Gastroenterol* 2009;103:774–83.
15. Arman S, Vijendren A, Lyons M. Outcome and follow-up of patients requiring emergency oesophagoscopy for food bolus obstruction over a 5-year period. *Otolaryngol Pol* 2019;74:29–32.
16. Ferrari D, Siboni S, Riva CG, et al. Esophageal foreign bodies: observational cohort study and factors associated with recurrent impaction. *Eur J Gastroenterol Hepatol* 2020;32:827–31.
17. Melgaard, D., Westmark, S., Laurberg P T, Krarup AL. A diagnostic delay of 10 years in the DanEoE cohort calls for focus on education – a population based cross sectional study of incidence, diagnostic process and complications of eosinophilic oesophagitis in the North Denmark Region. *United European Gastroenterol J* 2021;9:688–98.
18. Chang JW, Chen VL, Rubenstein JH, et al. What patients with eosinophilic esophagitis may not share with their providers: a qualitative assessment of online health communities. *Dis Esophagus* 2022;35:doab073.
19. Chang JW, Rubenstein JH, Mellinger JL, et al. Motivations, barriers, and outcomes of patient-reported shared decision making in eosinophilic esophagitis. *Dig Dis Sci* 2021;66:1808–17.
20. Hiremath, G. S. et al. Esophageal Food impaction and eosinophilic esophagitis: a retrospective study, systematic review, and meta-analysis. *Dig Dis Sci* 2015;60:3181–93.
21. Birk M, Bauerfeind P, Deprez PH, et al. Removal of foreign bodies in the upper gastrointestinal tract in adults: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. *Endoscopy* 2016;48:489–96.
22. Attwood S, Epstein J. Eosinophilic oesophagitis: recent advances and practical management. *Frontline Gastroenterol* 2020;12:644–9.
23. Ntuli Y, Bough I, Wilson M. Recognising eosinophilic oesophagitis as a cause of food bolus obstruction. *Frontline Gastroenterol* 2020;11:11–15.

References (2)

24. Marashi Nia SF, Meybodi MA, Sutton R, *et al.* Outcome, complication and follow-up of patients with esophageal foreign body impaction: an academic institute's 15 years of experience. *Dis Esophagus* 2020;**33**:doz103.
25. Donohue S, Hillman L, Lomeli L, Gaumnitz E. High rates of loss to follow-up after esophageal food impaction in suspected eosinophilic esophagitis: time to standardize care. *Am J Gastroenterol* 2019;**114**(Suppl):S269 (Abstract 460).
26. Chang JW, Olson S, Kim JY, *et al.* Loss to follow-up after food impaction among patients with and without eosinophilic esophagitis. *Dis Esophagus* 2019;**32**: doz056.
27. Lenz CJ, Leggett C, Katzka DA, *et al.* Food impaction: etiology over 35 years and association with eosinophilic esophagitis. *Dis Esophagus* 2019;**32**:doz010.
28. Hirano I, Moy N, Heckman M, *et al.* Endoscopic assessment of the oesophageal features of eosinophilic oesophagitis: Validation of a novel classification and grading system. *Gut* 2012;**62** 489-495.
29. Hillman L, Yadlapati R, Thuluvath AJ, *et al.* A review of medical therapy for proton pump inhibitor nonresponsive gastroesophageal reflux disease. *Dis Esophagus* 2021;**30**:1-15.
30. Beg S, Ragnunath K, Wyman A, *et al.* Quality standards in upper gastrointestinal endoscopy: a position statement of the British Society of Gastroenterology (BSG) and Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland (AUGIS). *Gut* 2017;**66**:1886-99.
31. Fiocca R, Mastracci L, Engström C, *et al.* Long-term outcome of microscopic esophagitis in chronic GERD patients treated with esomeprazole or laparoscopic antireflux surgery in the LOTUS trial. *Am J Gastroenterol* 2010;**105**:1015-23.
32. Wong S, Ruskiewicz A, Holloway RH, Nguyen NQ. Gastro-oesophageal reflux disease and eosinophilic oesophagitis: What is the relationship? *World J Gastrointest Pathophysiol* 2018;**9**:63-72.
33. Franciosi JP, Gordon M, Sinopoulou V, *et al.* Medical treatment of eosinophilic esophagitis. *Cochrane Database Syst Rev* 2023;**7**:CD004065.
34. UK Government. *Off-label or unlicensed use of medicines: prescribers' responsibilities*. 2014. Available at: <https://www.gov.uk/drug-safety-update/off-label-or-unlicensed-use-of-medicines-prescribers-responsibilities#in-practice> (accessed 1 February 2024).
35. Goyal A, Cheng E. Recent discoveries and emerging therapeutics in eosinophilic esophagitis. *World J Gastrointest Pharmacol Ther* 2016;**7**:21-32.
36. Kliewer KL, Gonsalves N, Dellon ES, *et al.* One-food versus six-food elimination diet therapy for the treatment of eosinophilic oesophagitis: a multicentre, randomised, open-label trial. *Lancet Gastroenterol Hepatol* 2023;**8**:408-21.
37. Molina-Infante J, Arias Á, Alcedo J, *et al.* Step-up empiric elimination diet for pediatric and adult eosinophilic esophagitis: The 2-4-6 study. *J Allergy Clin Immunol* 2018;**141**:1365-72.
38. Dellon ES, Liacouras CA, Molina-Infante J, *et al.* Updated international consensus diagnostic criteria for eosinophilic esophagitis: proceedings of the AGREE Conference. *Gastroenterology* 2018;**155**:1022-33.e10.
39. Laserna-Mendieta EJ, Casabona S, Guagnozzi D, *et al.* Efficacy of proton pump inhibitor therapy for eosinophilic oesophagitis in 630 patients: results from the EoE connect registry. *Aliment Pharmacol Ther* 2020;**52**:798-807.
40. Thakker KP, Fowler M, Keene S, *et al.* Long-term efficacy of proton pump inhibitors as a treatment modality for eosinophilic esophagitis. *Dig Liv Dis* 2022;**54**:1179-85.
41. Schroeder S, Atkins D, Furuta GT. Recent advances in the treatment of eosinophilic esophagitis. *Exp Rev Clin Immunol* 2010;**6**:929-37.
42. Straumann A, Katzka DA. Diagnosis and treatment of eosinophilic esophagitis. *Gastroenterology* 2018;**154**:346-59.
43. Alexander JA. Topical steroid therapy for eosinophilic esophagitis. *Gastroenterol Hepatol* 2014;**10**:327-9.

References (3)

44. Dohil R, Newbury R, Fox L, et al. Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial. *Gastroenterology* 2010;**139**:418–29.
45. Straumann A, Conus S, Degen L, et al. Budesonide is effective in adolescent and adult patients with active eosinophilic esophagitis. *Gastroenterology* 2010;**139**:1526–37.
46. Konikoff MR, Noel RJ, Blanchard C, et al. A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis. *Gastroenterology* 2006;**131**:1381–91.
47. Dr. Falk Pharma GmbH. *Jorveza 0.5 mg orodispersible tablets; Jorveza 1 mg orodispersible tablets*. Available at: <http://www.medicines.org.uk/emc/product/9446> (accessed 1 February 2024).
48. European Medicines Agency. Assessment report: *Jorveza, International non-proprietary name: budesonide*. Available at: http://www.ema.europa.eu/en/documents/assessment-report/jorveza-epar-public-assessment-report_en.pdf (accessed 1 February 2024).
49. Alexander JA, Katka DA. Therapeutic options for eosinophilic esophagitis. *Gastroenterol Hepatol* 2011;**7**:59–61.
50. Miehke S, Schlag C, Lucendo AJ, et al. Budesonide orodispersible tablets for induction of remission in patients with active eosinophilic oesophagitis: a 6-week open-label trial of the EOS-2 Programme. *UEG J* 2022;**10**:330–43.
51. National Institute for Health and Care Excellence (NICE). Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis. Available at: <http://www.nice.org.uk/guidance/ta708> (accessed 1 February 2024).
52. Lucendo AJ, Miehke S, Schlag C, et al. Efficacy of budesonide orodispersible tablets as induction therapy for eosinophilic esophagitis in a randomized placebo-controlled trial. *Gastroenterology* 2019;**157**:74–86.
53. Dellon ES, Woosley JT, Arrington A, et al. Rapid recurrence of eosinophilic esophagitis activity after successful treatment in the observation phase of a randomized, double-blind, double-dummy trial. *Clin Gastroenterol Hepatol* 2020;**18**:1483–92.e2.
54. Straumann A, Lucendo AJ, Miehke S, et al. Budesonide orodispersible tablets maintain remission in a randomized, placebo-controlled trial of patients with eosinophilic esophagitis. *Gastroenterology* 2020;**159**:1672–85.e5.
55. Schlag C, Straumann A, Lucendo AJ, Miehke S. Budesonide orodispersible tablets maintain clinical, histological and endoscopic remission in adult patients with eosinophilic esophagitis: results from the 96-weeks open-label extension phase following the 1-year double-blind EOS-2 trial. *Gastroenterology* 2022;**162**:S-213.
56. National Institute for Health and Care Excellence (NICE). Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis: history. Available at: <https://www.nice.org.uk/guidance/ta708/history> (accessed 1 February 2024).
57. Miehke S, Lucendo AJ, Straumann A, et al. Orodispersible budesonide tablets for the treatment of eosinophilic esophagitis: a review of the latest evidence. *Therap Adv Gastroenterol.* 2020;**13**.

Contributors

The optimal pathway described in this document has been developed based on consensus of an expert group combined with insights from interviews with stakeholders involved at all stage of the pathway.

| Expert group 1 |
|---|
| Stephen Attwood (chair) , Honorary Professor, Health Services Research, Durham University, England |
| Dr Hasan Haboubi , Consultant Gastroenterologist, Cardiff & Vale University Health Board, Cardiff, Wales |
| Dr Amir Jehangir , Consultant in Acute Internal Medicine, University College London Hospitals NHS Foundation Trust, London, England |
| Helen Morgan , Lead Clinical Pharmacist, Gastroenterology & Hepatology, Chelsea and Westminster Hospital NHS Foundation Trust, London, England |
| Dr Maxton Pitcher , Consultant Gastroenterologist, St Mark's and Northwick Park Hospital, London, England |
| Dr Terry Wong , Consultant Gastroenterologist, Guy's and St Thomas' NHS Foundation Trust, London, England |

| Expert group 2 |
|--|
| Stephen Attwood (chair) , Honorary Professor, Health Services Research, Durham University, England |
| Dr Kumar Basu , Gastroenterologist, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, England |
| Dr Joseph Cooney , Gastroenterology Registrar at St George's University Hospitals NHS Foundation Trust, London, England |
| Professor Anjan Dhar , Professor of Medicine, School of Health & Life Sciences, Teesside University; Consultant Luminal Gastroenterologist, Advanced Endoscopist & Research Lead for GI; Chair of Education & Council Member; British Society of Gastroenterology (BSG), Middlesbrough, England |
| Dr Marion Sloan , GP Partner with Special Interest in Gastroenterology, Sloan Medical Centre, Sheffield, England |
| Mr Rupesh Thakkar , Chief Pharmacist, Solihull Healthcare Partnership, Solihull, England |

Development of this optimal pathway was supported by Wilmington Healthcare, funded by an educational grant from Dr Falk.

Supporting information

Adverse events should be reported. In the UK visit www.mhra.gov.uk/yellowcard. In Ireland: <https://www.hpra.ie/homepage/about-us/report-an-issue/human-adverse-reaction-form>.

Adverse events should also be reported to Dr Falk Pharma UK Ltd on pv@drfalkpharma.co.uk or 0044 (0)1628 536600.

Prescribing Information (refer to full SmPC before prescribing).

Presentations: Jorveza 1 mg and 0.5 mg orodispersible tablets containing 1 mg or 0.5 mg of budesonide. Indications: treatment of eosinophilic esophagitis (EoE) in adults (older than 18 years of age). Dosage: Induction of remission: one 1 mg tablet taken twice daily (morning and evening) after a meal and immediately after removal of the tablet from the blister pack. Usual duration of induction treatment is 6 weeks. Extend up to 12 weeks for non-responding patients. Maintenance of remission: 0.5 mg twice daily or 1 mg twice daily depending on clinical need. A maintenance dose of 1 mg twice daily is recommended for patients with long-standing disease history and/or high extent of esophageal inflammation in the acute disease state. Duration of maintenance treatment - to be determined by the treating physician. Administration: tablet is placed on tip of tongue and pressed to top of mouth then swallowed slowly without liquid or food and without chewing or swallowing undissolved. May take 2 to 20 minutes to disintegrate and swallow completely. Wait at least 30 minutes before eating, drinking or performing oral hygiene. Contra-indications: hypersensitivity to budesonide or any ingredient of the tablets. Warnings/precautions: infections - Suppression of inflammatory response and immune function increases susceptibility to infections and their severity which can be atypical or masked. Oral, oropharyngeal and esophageal candida infections occur at high frequency. Treat symptoms with topical or systemic anti-fungals. Jorveza treatment can continue. Chickenpox, herpes zoster and measles - can be more serious in patients treated with glucocorticosteroids. Check vaccination status. Avoid exposure. Vaccines - avoid co-administration of live vaccines and glucocorticosteroids. The antibody response to other vaccines may be diminished. Special populations - monitor patients with tuberculosis, hypertension, diabetes mellitus, osteoporosis, peptic ulcer, glaucoma, cataract, family history of diabetes, family history of glaucoma. Systemic effects of glucocorticosteroids may occur, depending on duration of treatment, concomitant and previous glucocorticosteroid treatment and individual sensitivity. Patients with reduced liver function - an increased systemic availability of budesonide may be expected, with increased risk of adverse reactions.

Patients with hepatic impairment should not be treated. Not recommended for use in patients with severe renal impairment. Angioedema - treatment should be stopped if signs of angioedema are observed. Visual disturbance - patients with blurred vision or other visual disturbances should be considered for referral to an ophthalmologist. Causes may include cataract, glaucoma or central serous chorioretinopathy resulting from corticosteroid use. Others - glucocorticosteroids may cause suppression of the hypothalamic-pituitary-adrenal (HPA) axis and reduce the stress response. When patients are subject to surgery or other stresses, supplementary systemic glucocorticosteroid treatment is therefore recommended. Concomitant treatment with ketoconazole or other CYP3A4 inhibitors should be avoided. Serological testing - adrenal function may be suppressed by budesonide so an ACTH stimulation test for diagnosing pituitary insufficiency might show false (low) results. Sodium - contains 52 mg of sodium per daily dose. Interactions: CYP3A4 inhibitors - concomitant treatment with ketoconazole or other potent CYP3A4 inhibitors including grapefruit juice should be avoided to reduce the risk of systemic side effects unless the benefit outweighs the risk. Such treatment should be monitored.

Oestrogens, oral contraceptives - may elevate plasma concentrations and enhance effects of glucocorticosteroids. Concomitant intake of low-dose combination oral contraceptives has not shown this effect. Cardiac glycosides - action of glycoside can be potentiated by potassium deficiency - a potential and known adverse reaction of glucocorticosteroids. Saluretics - potassium excretion can be enhanced and hypokalaemia aggravated. Use in pregnancy should be avoided unless there are compelling reasons for therapy. Breast-feeding - budesonide is excreted in human milk. The benefit of breast feeding for the child and the benefit of therapy for the woman should be assessed. Fertility - there are no data on the effect of budesonide on human fertility. Undesirable effects: fungal infections in the mouth, pharynx and the oesophagus were the most frequently observed adverse reactions

in clinical studies. Long term treatment did not increase the rate. Adverse reactions and frequencies: Very common: esophageal candidiasis, oral and/or oropharyngeal candidiasis,

Common: sleep disorder, headache, dysgeusia, dry eyes, gastroesophageal reflux disease, nausea, oral paraesthesia, dyspepsia, upper abdominal pain, dry mouth, glossodynia, tongue disorder, oral herpes, fatigue, blood cortisol decreased. Uncommon: nasopharyngitis, pharyngitis, angioedema, , anxiety, agitation, dizziness, , hypertension, cough, dry throat, oropharyngeal pain, abdominal pain, abdominal distension, , dysphagia, erosive gastritis, gastric ulcer, lip edema, gingival pain, rash, urticaria, sensation of foreign body, osteocalcin decreased, weight increased. . Other (class) effects with unknown frequency that may occur: increased risk of infection, Cushing's syndrome, adrenal suppression, growth retardation in children, hypokalaemia, hyperglycaemia, depression, irritability, euphoria, psychomotor hyperactivity, aggression, pseudotumor cerebri including papilloedema in adolescents, glaucoma, cataract (including subcapsular cataract), blurred vision, central serous chorioretinopathy (CSCR), increased risk of thrombosis, vasculitis (withdrawal syndrome after long-term therapy), duodenal ulcers, pancreatitis, constipation, allergic exanthema, petechiae, delayed wound healing, contact dermatitis, ecchymosis, muscle and joint pain, muscle weakness and twitching, osteoporosis, osteonecrosis, malaise.

Legal category: POM. **Cost:** 1 mg - pack of 90 - £323; 0.5 mg - pack of 60 - £214.80. Not currently available in Ireland. **Product licence holder:** Dr. Falk Pharma GmbH. **Product licence number:** IE/Nl: 1 mg: EU/1/17/1254/004, 0.5 mg: EU/1/17/1254/008. GB: 1 mg: PLGB08637/0030; 0.5 mg: PLGB08637/0032. **Date of preparation:** February 2023.

Further information is available on request.



Wilmington Healthcare

With unparalleled NHS expertise and outstanding industry knowledge, Wilmington Healthcare offers data, data visualisation, insight and analysis across the full spectrum of UK healthcare. We deliver sustainable outcomes for NHS suppliers and ultimately patients.

We hope you found this pathways document useful. Much of the insight contained in this document is drawn from Wilmington Healthcare's portfolio of data and intelligence solutions, curated by our team of experts and consultants.

For more information or to request a demo of a solution please contact us in any of the following ways:

w: wilmingtonhealthcare.com

e: info@wilmingtonhealthcare.com

 [@WilmHealthcare](https://twitter.com/WilmHealthcare)

 [Wilmington Healthcare](https://www.linkedin.com/company/wilmington-healthcare)

[#WilmHealth](https://twitter.com/WilmHealthcare)

Wilmington Healthcare is part of Wilmington plc www.wilmingtonplc.com
Registered in England and Wales, Reg No. 2530185

